ArticleBritish journal of pharmacology1994
Evidence that nitric oxide is an endogenous antiangiogenic mediator.
Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 165 citations in OpenAlex.
- Electronic structure and mechanism for the uptake of nitric oxide by the Ru(iii) antitumor complex NAMI-A.RSC advances · 2021Article
- Histological assessment of the local effect of different concentrations of aminoguanidine hydrochloride on bone healing in rats.Dental research journal · 2021Article
- CDC-derived extracellular vesicles reprogram inflammatory macrophages to an arginase 1-dependent proangiogenic phenotype.American journal of physiology. Heart and circulatory physiology · 2020Article
- Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.Free radical biology & medicine · 2015Article
- Effect of Blocking of Neuropeptide Y Y2 Receptor on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 Mice.Global journal of health science · 2015Article
- The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.Pharmaceuticals (Basel, Switzerland) · 2010Review
- JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.The Journal of pharmacy and pharmacology · 2010Article
- Growth factor activation in myocardial vascularization: therapeutic implications.Molecular and cellular biochemistry · 2004Review
- Nitric oxide signaling during myocardial angiogenesis.Molecular and cellular biochemistry · 2004Review
- Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth.British journal of cancer · 2003Article
- Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.Gene therapy · 2002Article
- Endogenously produced nitric oxide inhibits endothelial cell growth as demonstrated using novel antisense cell lines.British journal of pharmacology · 2000Article
- Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane.British journal of pharmacology · 2000Article
- Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth.The Journal of experimental medicine · 1998Article
- Effects of low dose ionizing radiation on murine chronic granulomatous tissue.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 1998Article
- Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.The Journal of clinical investigation · 1998Article
- Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.The Journal of clinical investigation · 1997Article
- Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.The Journal of clinical investigation · 1997Article
- Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro.The American journal of pathology · 1997Article
- In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity.British journal of cancer · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The involvement of nitric oxide (NO) in the regulation of angiogenesis was examined in the in vivo system of the chorioallantoic membrane (CAM) of the chick embryo and in the matrigel tube formation assay. 2. Sodium nitroprusside (SNP) (0.37-28 nmol/disc), which releases NO spontaneously, caused a dose-dependent inhibition of angiogenesis in the CAM in vivo and reversed completely the angiogenic effects of alpha-thrombin (6.7 nmol/disc) and the protein kinase C (PKC) activator 4-beta-phorbol-12-myristate-13-acetate (PMA) (0.97 nmol/disc). In addition, SNP (28 x 10(-6) M) stimulated the release of guanosine 3'-5'-cyclic monophosphate (cyclic GMP) from the CAM in vitro. 3. In the matrigel tube formation assay, an in vitro assay of angiogenesis, both SNP (1-3 x 10(-6) M) and the cell permeable cyclic GMP analogue, Br-cGMP (0.3-1.0 x 10(-3) M) reduced tube formation. 4. The inhibitors of NO synthase, NG-monomethyl-L-arginine (L-NMMA) (3.8-102 nmol/disc) and NG-nitro-L-arginine methylester (L-NAME) (1.3-34.2 nmol/disc) stimulated angiogenesis in the CAM in vivo, in a dose-dependent fashion. D-NMMA and D-NAME on the other hand had no effect on angiogenesis in this system. 5. L-Arginine (10.9 nmol/disc), although it had a modest antiangiogenic effect by itself, was capable of abolishing the angiogenic effects of L-NMMA (34.2 nmol/disc) and of L-NAME (3.8 nmol/disc). 6. Dexamethasone, an inhibitor of the induction of NO synthase, at 0.2-116.1 nmol/disc, stimulated angiogenesis in the CAM, whereas at 348.4-1161 nmol/disc it inhibited this process. Combination of 38.7 nmol/disc dexamethasone with L-NAME (9.3 nmol/disc) resulted in a potentiation of the angiogenic effect of the former. It appears therefore that both the constitutive and the inducible NO synthase may contribute to the NO-mediated inhibition of angiogenesis. 7. Superoxide dismutase (SOD), which prevents the destruction of NO, at 300 i.u./disc had a modest antiangiogenic effect in the CAM, by itself. In addition, SOD, prevented alpha-thrombin (6.7 nmol/disc) and PMA (0.97 nmol/disc) from stimulating angiogenesis in the CAM.8. These results suggest that NO may be an endogenous antiangiogenic molecule of pathophysiological importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.